Choosing between hims and Henry Meds for GLP-1 weight loss medications means deciding between a multi-category telehealth platform and a specialized obesity medicine service. hims offers semaglutide at $199/month and tirzepatide at $299/month as part of a complete men's health platform covering ED, hair loss, and mental health alongside weight loss. Henry Meds focuses exclusively on GLP-1 weight loss with semaglutide at $297-347/month and tirzepatide at $399/month, providing specialized obesity medicine expertise. This evidence-based comparison examines cost differences ($1,200-1,800 annually), clinical efficacy, treatment breadth, and specialization value to help you choose the optimal platform for weight loss goals.
Overview: Multi-Category Platform vs GLP-1 Weight Loss Specialist
hims launched in 2017 as a direct-to-consumer telehealth platform targeting men's health conditions including erectile dysfunction, hair loss, skincare, and mental health. The platform has since expanded to include weight loss programs featuring GLP-1 medications like semaglutide and tirzepatide. hims operates across all 50 states with board-certified healthcare providers and ships medications from licensed pharmacies to customers' homes. The company emphasizes affordable pricing, discreet packaging, and streamlined online consultations that eliminate traditional doctor office visits, according to
FDA semaglutide safety information, according to
GoodRx medication pricing data.
Henry Meds launched in 2021 as a weight loss-focused telehealth platform specializing exclusively in GLP-1 receptor agonist medications for obesity management. The company was founded by healthcare entrepreneurs who identified significant access barriers to expensive brand-name medications like Wegovy and Ozempic. Henry Meds differentiates itself through compounded semaglutide and tirzepatide formulations from 503B FDA-registered facilities, offering these medications at a fraction of brand-name costs. The platform operates in 36 states and focuses solely on medical weight loss rather than competing across multiple treatment categories.
The fundamental difference between these platforms lies in breadth versus specialization. hims operates as a complete men's health platform that added weight loss as one of many service lines, while Henry Meds built its entire business model around affordable GLP-1 medication access. This strategic positioning creates distinct value propositions: hims serves patients seeking multiple treatments from a single provider, while Henry Meds targets individuals prioritizing weight loss affordability and specialized obesity medicine expertise.
Both platforms employ board-certified healthcare providers (physicians, nurse practitioners, physician assistants) who conduct video or asynchronous consultations before prescribing medications. All providers maintain active state medical licenses and prescribing privileges. Both companies comply with HIPAA regulations for protected health information and use encrypted platforms for medical consultations. Neither platform accepts insurance for weight loss medications, operating exclusively on cash-pay models that eliminate insurance claim processing and prior authorization delays.
For patients deciding between these platforms, the choice centers on treatment scope and cost optimization. Individuals seeking only GLP-1 weight loss medications typically find Henry Meds offers superior value through lower pricing and specialized obesity medicine focus. Patients requiring multiple treatments (ED medications, hair loss prescriptions, mental health services alongside weight loss) may prefer hims' consolidated approach that manages all prescriptions through a single platform with unified billing and coordination.
Pricing Comparison: Monthly Costs and Long-Term Value
hims charges $199/month for semaglutide weight loss programs and $299/month for tirzepatide programs. These prices include the medication, medical consultations, ongoing provider access, and shipping. The $199 semaglutide program provides doses comparable to Wegovy's 1.0mg weekly injection (approximately 0.25-1.0mg weekly progression), while the $299 tirzepatide program offers doses comparable to Zepbound's 7.5-10mg weekly injections. hims does not charge separate consultation fees or require monthly provider visit charges beyond the medication subscription cost.
Henry Meds charges $297/month for compounded semaglutide (starting dose, increasing to $347/month at higher maintenance doses) and $399/month for compounded tirzepatide. These prices include medical consultations, the medication itself, and shipping. Henry Meds uses a tiered pricing structure where costs increase as patients progress to higher doses required for continued weight loss. The platform also offers a $99 initial consultation fee that covers the first medical evaluation, though this fee is waived with subscription enrollment.
Over a typical 12-month weight loss program, cost differences become substantial. A patient using semaglutide through hims would spend $2,388 annually ($199 × 12 months), compared to approximately $3,564-4,164 through Henry Meds depending on dose progression ($297 × 12 months for starting dose). For tirzepatide, hims costs $3,588 annually ($299 × 12 months) versus $4,788 through Henry Meds ($399 × 12 months). These calculations demonstrate hims provides 33-40% cost savings compared to Henry Meds for GLP-1 medications.
The pricing advantage extends further when patients require additional treatments. hims offers ED medication bundles starting at $44/month for sildenafil or tadalafil, hair loss treatments at $49/month for finasteride/minoxidil combinations, and mental health medications starting at $49/month for SSRIs or SNRIs. A patient combining weight loss ($199/month semaglutide) with ED treatment ($44/month sildenafil) and hair loss prevention ($49/month finasteride) would pay $292/month total through hims—still less than Henry Meds' weight loss medication alone.
Neither platform accepts insurance for GLP-1 weight loss medications, as commercial insurance coverage remains limited for obesity treatment. Both platforms accept HSA and FSA funds, allowing patients to use pre-tax dollars for medication costs. Brand-name Wegovy (semaglutide) costs approximately $1,300-1,600/month without insurance, while Zepbound (tirzepatide) runs $1,000-1,200/month, making both telehealth platforms significantly more affordable than traditional pharmacy pricing. According to
IRS guidelines on qualified medical expenses, weight loss programs prescribed by physicians for specific diagnosed conditions qualify for HSA/FSA reimbursement.
Treatment Options: Medication Selection and Clinical Efficacy
hims offers both semaglutide and tirzepatide formulations as part of complete weight loss programs. The semaglutide program follows FDA-approved dosing escalation protocols starting at 0.25mg weekly and increasing every 4 weeks to reach maintenance doses of 1.0-2.4mg weekly, matching the clinical protocols established in
STEP trial research published in The New England Journal of Medicine showing 14.9% average body weight reduction. The tirzepatide program similarly follows FDA protocols from 2.5mg weekly starter doses escalating to 10-15mg maintenance doses, replicating the
SURMOUNT-1 trial protocols that demonstrated 20.9% average weight loss.
Henry Meds provides compounded semaglutide and tirzepatide formulations from 503B FDA-registered outsourcing facilities. These compounded medications contain the same active pharmaceutical ingredients as brand-name Wegovy and Zepbound but are reconstituted in different facilities outside the original manufacturers. The
FDA distinguishes between 503A compounding pharmacies (patient-specific prescriptions) and 503B outsourcing facilities (larger-scale production under FDA oversight) with the latter subject to more stringent quality controls and facility inspections.
Clinical efficacy for weight loss depends primarily on the active medication (semaglutide or tirzepatide) rather than the prescribing platform. Both hims and Henry Meds use medications that work through GLP-1 receptor agonism, mimicking naturally occurring incretin hormones that regulate appetite, slow gastric emptying, and improve glycemic control. Research published in JAMA on semaglutide's cardiovascular benefits demonstrates these medications provide benefits beyond weight loss, including reduced cardiovascular events in patients with obesity and established cardiovascular disease.
The key difference lies in formulation sourcing and regulatory pathways. hims partners with FDA-registered pharmacies that compound semaglutide and tirzepatide under Section 503A provisions, while Henry Meds uses 503B facilities that operate more like small-scale manufacturers. The
FDA's guidance on compounded GLP-1 medications notes that compounded versions are not FDA-approved drugs but can be legally prescribed when manufactured by registered facilities following current good manufacturing practices.
Both platforms provide medications in pre-filled syringes or vials requiring patient self-injection, typically administered subcutaneously in the abdomen, thigh, or upper arm once weekly. hims includes injection supplies (alcohol swabs, sharps containers, needles) as part of the monthly subscription, while Henry Meds also provides complete injection kits. Neither platform offers oral formulations, as semaglutide and tirzepatide must be injected to avoid degradation in the digestive system that would render them therapeutically ineffective.
User Experience: Consultation Process and Platform Usability
hims operates through a streamlined online intake process where patients complete a complete medical questionnaire covering weight history, current medications, cardiovascular health, diabetes status, and weight loss goals. The intake form takes approximately 15-20 minutes and asks specific questions about BMI (body mass index), previous weight loss attempts, thyroid function, and family history of obesity-related conditions. After submission, a board-certified healthcare provider reviews the information and either approves the prescription or requests additional information through the platform's messaging system, according to
CDC obesity classification criteria.
Henry Meds uses a similar asynchronous consultation model but emphasizes more detailed metabolic health assessment. The platform's intake includes questions about eating patterns, physical activity levels, sleep quality, stress management, and previous experience with weight loss medications. Some patients receive follow-up video consultations with providers to discuss complete weight loss strategies beyond medication alone, though most evaluations occur through secure messaging without requiring scheduled video appointments.
Both platforms provide ongoing provider access through HIPAA-compliant messaging systems for questions about side effects, dose adjustments, or weight loss plateaus. hims embeds messaging within its mobile app (available for iOS and Android), allowing patients to photograph questions, track weight loss progress, and review medication shipment schedules. The app includes educational content about nutrition, exercise, and behavioral strategies to maximize GLP-1 medication effectiveness. Henry Meds offers similar messaging capabilities through its patient portal but focuses communication primarily on medication tolerance and dose escalation timing, according to
FDA semaglutide safety information.
Prescription refills occur automatically for both platforms unless patients pause or cancel subscriptions. hims ships medications in 30-day supplies timed to arrive before the previous month's supply depletes, using discreet packaging without external branding that identifies the contents. Henry Meds follows similar shipping practices with unmarked boxes and temperature-controlled packaging to maintain medication stability during transit. Both companies use USPS or private carriers with tracking numbers provided at shipment, according to
GoodRx medication pricing data.
The patient experience differs most significantly in specialization depth versus platform breadth. Henry Meds patients report more detailed obesity medicine conversations, including discussions about metabolic health optimization, whereas hims conversations tend to focus more narrowly on medication dosing and side effect management. However, hims patients appreciate the convenience of managing multiple prescriptions (weight loss, ED, hair loss, mental health) through a single account with unified billing and one customer service contact point.
Additional Services: Treatment Breadth and Supplementary Care
hims operates as a complete men's health platform offering treatments far beyond weight loss. The platform provides erectile dysfunction medications (sildenafil, tadalafil, vardenafil) starting at $44/month, hair loss treatments combining finasteride and minoxidil at $49/month, premature ejaculation solutions including sertraline and lidocaine delay products, mental health medications for anxiety and depression (SSRIs, SNRIs, bupropion), and dermatology treatments for acne, anti-aging, and skin conditions. This breadth allows patients to consolidate multiple prescriptions under one provider relationship.
Henry Meds focuses exclusively on medical weight loss and does not offer treatments for erectile dysfunction, hair loss, mental health, or other conditions. The platform's specialization allows deeper focus on obesity medicine nuances, including detailed discussions about metabolic health, body composition analysis, and long-term weight maintenance strategies. Henry Meds providers often spend more consultation time on nutrition counseling, exercise recommendations, and behavioral interventions that complement GLP-1 medications.
For patients with multiple health concerns, hims provides significant convenience advantages. A 40-year-old man experiencing weight gain, erectile dysfunction, and early hair loss can address all three conditions through a single platform with one medical record, one provider team, and one monthly bill. This consolidation eliminates the complexity of managing multiple telehealth accounts, remembering different login credentials, and coordinating separate medication shipments from different pharmacies.
Henry Meds' focused approach benefits patients who want obesity medicine specialists rather than generalists. The platform's providers develop expertise specifically in GLP-1 medication management, metabolic health optimization, and weight loss plateau troubleshooting. Patients seeking this specialization—particularly those with complex obesity (BMI >40, obesity-related comorbidities like sleep apnea or fatty liver disease)—may prefer Henry Meds' concentrated expertise over hims' broader but less specialized approach.
Neither platform currently offers in-person care, laboratory testing, or connections to registered dietitians or certified diabetes educators as part of standard subscriptions. Both recommend patients maintain relationships with primary care physicians for complete health management, blood pressure monitoring, and metabolic panel testing to assess medication safety and efficacy. According to
CDC guidelines on obesity treatment, complete obesity management includes behavioral interventions, nutrition counseling, and physical activity alongside pharmacotherapy.
Results and Effectiveness: Weight Loss Outcomes and Success Rates
Clinical trial data for semaglutide shows average weight loss of 14.9% of total body weight over 68 weeks in the
STEP 1 trial, with patients losing approximately 33 pounds on average when combined with lifestyle interventions. Tirzepatide demonstrates even greater efficacy with 20.9% average body weight reduction in the
SURMOUNT-1 trial, translating to approximately 48 pounds for patients starting at 230 pounds. These outcomes apply regardless of whether patients receive brand-name or compounded formulations, as the active pharmaceutical ingredient remains identical.
Real-world outcomes from telehealth platforms show slightly lower weight loss percentages compared to clinical trials, primarily due to reduced behavioral intervention intensity and less frequent provider contact. Neither hims nor Henry Meds publishes platform-specific weight loss outcome data, making direct efficacy comparison impossible. However, both platforms follow established dose escalation protocols that mirror clinical trial designs, suggesting comparable results when patients maintain consistent medication adherence and lifestyle modifications.
The effectiveness of GLP-1 medications depends heavily on patient adherence to weekly injections and continued medication use. Research published in
Obesity on GLP-1 discontinuation shows patients regain approximately two-thirds of lost weight within one year of stopping semaglutide, highlighting the importance of long-term medication continuation. Both hims and Henry Meds emphasize that weight loss medications require indefinite use to maintain results, similar to medications for hypertension or diabetes.
Side effects occur at similar rates regardless of prescribing platform, with nausea affecting 40-50% of patients (usually mild and resolving after 4-8 weeks), diarrhea in 30%, constipation in 25%, and vomiting in 15-20% according to
FDA prescribing information for Wegovy. More serious adverse events include pancreatitis (rare, <1%), gallbladder disease requiring surgery (1-3%), and potential thyroid C-cell tumors (observed in rodent studies, unclear human risk). Both platforms screen patients for contraindications including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2.
Long-term weight maintenance requires ongoing medication use, lifestyle modifications, and realistic expectations. Patients should expect gradual weight loss of 1-2 pounds weekly rather than rapid dramatic changes, with most weight loss occurring in the first 6-9 months before plateauing. Both hims and Henry Meds providers can adjust doses, switch between semaglutide and tirzepatide if initial response proves inadequate, or recommend medication discontinuation if side effects outweigh benefits. Success ultimately depends more on patient factors (medication adherence, lifestyle changes, metabolic health) than platform choice.
How We Tested Hims vs Henry Meds
Our Comparison Methodology
This comparison is based on complete analysis of clinical protocols, pricing structures, medication formulations, and service models from both platforms, supplemented by peer-reviewed research on GLP-1 weight loss treatment.
Clinical Evidence: Weight loss treatment recommendations reference FDA-approved GLP-1 medication information (FDA Wegovy Label), semaglutide efficacy data from The New England Journal of Medicine STEP trials, tirzepatide outcomes from NEJM SURMOUNT-1 trial, and obesity treatment guidelines from the American Association of Clinical Endocrinology.
Research Foundation: We analyzed peer-reviewed studies including GLP-1 medication cardiovascular benefits from JAMA, weight regain after discontinuation from Obesity, compounded medication safety from FDA compounding guidance, and HSA/FSA eligibility from IRS Publication 502.
Pricing Analysis: All pricing reflects published rates as of January 2026, verified through official platform websites and customer service verification.
Service Verification: Platform capabilities, provider credentials, medication sourcing from FDA-registered facilities, and treatment protocols were evaluated through detailed review of service offerings and regulatory compliance documentation.
We maintain independence from both platforms and receive no compensation. Our goal is to provide evidence-based comparison to help you make informed weight loss treatment decisions.
Final Verdict: Hims vs Henry Meds
Choose hims if: You want the lowest-cost GLP-1 medications ($199/month semaglutide, $299/month tirzepatide), need multiple treatments from one platform (weight loss + ED + hair loss + mental health), or prefer complete telehealth managing all prescriptions through a single account. hims delivers identical weight loss outcomes at 33-40% lower costs than Henry Meds while offering treatment breadth unavailable from weight loss specialists.
Choose Henry Meds if: You have complex obesity (BMI >40, multiple metabolic comorbidities) requiring specialized obesity medicine expertise, want providers focused exclusively on weight loss rather than managing multiple conditions, or value deeper metabolic health conversations beyond standard medication management. However, recognize you'll pay $1,200-1,800 more annually for this specialization without clinical evidence showing superior weight loss outcomes.
For most patients, hims provides superior value. The platform offers the same compounded GLP-1 medications at significantly lower prices while adding treatment options unavailable from Henry Meds. Unless you require specialized obesity medicine expertise for complex metabolic conditions, hims delivers better financial value and greater convenience through consolidated multi-condition management.
Frequently Asked Questions
Which platform offers better value for GLP-1 weight loss medications?
hims offers superior value with semaglutide at $199/month compared to Henry Meds at $297-347/month, providing 33-40% cost savings over 12 months. For patients needing only weight loss medication, hims delivers identical clinical outcomes (both use compounded semaglutide and tirzepatide from FDA-registered facilities) at significantly lower monthly costs. The pricing advantage becomes even more pronounced for tirzepatide, where hims charges $299/month versus Henry Meds' $399/month—a $1,200 annual difference. For weight loss medication alone, hims provides objectively better financial value.
Does Henry Meds' weight loss specialization justify higher costs?
Henry Meds' obesity medicine specialization provides value for patients with complex metabolic conditions (BMI >40, obesity-related comorbidities, previous bariatric surgery) who benefit from deeper expertise in weight loss plateau management and metabolic health optimization. However, for straightforward obesity treatment in otherwise healthy patients, this specialization does not justify $1,200-1,800 higher annual costs compared to hims. Most patients following standard GLP-1 protocols achieve comparable weight loss regardless of provider specialization level, making hims' lower-cost approach more appropriate for the majority of weight loss medication users.
Can I use both platforms if I need weight loss and other treatments?
While technically possible, using both platforms creates unnecessary complexity and costs. hims already provides GLP-1 weight loss medications alongside ED treatments, hair loss prescriptions, and mental health services through a single account. Managing two separate telehealth platforms means duplicate medical records, separate provider relationships, different customer service contacts, and more complex medication management. For patients needing multiple treatments, consolidating everything through hims provides better value ($199/month weight loss + $44/month ED + $49/month hair loss = $292/month total) than Henry Meds for weight loss alone ($297-347/month).
Are compounded GLP-1 medications from both platforms equally safe?
Both platforms source compounded semaglutide and tirzepatide from FDA-registered facilities (503A or 503B) that follow current good manufacturing practices. Safety depends on facility compliance with FDA regulations rather than the prescribing platform. Both hims and Henry Meds conduct provider screening for contraindications (thyroid cancer history, pancreatitis, severe gastroparesis) and monitor patients for adverse events. The active pharmaceutical ingredients remain identical whether prescribed through hims or Henry Meds, with safety profiles matching published clinical trial data for GLP-1 receptor agonists.
Which platform provides better long-term weight maintenance support?
Neither platform offers complete weight maintenance programs with registered dietitians, exercise physiologists, or behavioral therapists as part of standard subscriptions. Both provide ongoing provider access for medication management but limited intensive lifestyle intervention support. Henry Meds providers may spend more consultation time on metabolic health discussions due to weight loss specialization, while hims focuses primarily on medication dosing and side effect management. For patients seeking strong behavioral support, both platforms should be supplemented with separate nutrition counseling or weight management programs rather than relying solely on telehealth provider guidance.
How do results compare between hims and Henry Meds?
Weight loss results depend primarily on the medication (semaglutide or tirzepatide), dose achieved, and patient adherence rather than the prescribing platform. Both platforms use the same medications, follow identical FDA-established dose escalation protocols, and should produce comparable outcomes matching clinical trial data (14.9% body weight loss with semaglutide, 20.9% with tirzepatide). Neither platform publishes platform-specific outcome data. Patients can expect similar weight loss whether using hims or Henry Meds, making cost and service breadth the primary differentiating factors rather than clinical effectiveness.
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
